U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07938073) titled 'Phase 2 Study Of IDH 1/2 Inhibitor Vorasidenib In Patients With IDH2-Mutated Intrahepatic Cholangiocarcinoma' on Nov. 10.

Brief Summary: To find the recommended dose of vorasidenib that can be given to participants with IDH2-mutated iCCA.

Study Start Date: April 29, 2027

Study Type: INTERVENTIONAL

Condition: IDH2-Mutated Intrahepatic Cholangiocarcinoma

Intervention: DRUG: Vorasidenib

Give by po

Recruitment Status: NOT_YET_RECRUITING

Sponsor: M.D. Anderson Cancer Center

Published by HT Digital Content Services with permission from Health Daily Digest....